Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Recommendation of Buy from Analysts

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has received a consensus rating of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have updated their coverage on the stock in the […]

Related Keywords

United States ,America ,Arthura Levin , ,Raymond James Financial Services Advisors Inc ,Avidity Biosciences Inc ,Securities Exchange Commission ,Cantor Fitzgerald ,Mirae Asset Global Investments Co ,Needham Company ,Vanguard Group Inc ,Nasdaq ,Avidity Biosciences Company Profile ,Avidity Biosciences ,Get Free Report ,Chardan Capital ,Director Arthur ,Exchange Commission ,Capital Partners ,Asset Global Investments ,Raymond James Financial Services Advisors ,James Financial Services Advisors ,Get Free ,Avidity Biosciences Daily ,Nasdaq Rna ,Rna ,Medical ,Ratings ,Consensus ,